These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 29580554)
1. Paramunity-inducing Factors (PINDs) in dendritic cell (DC) cultures lead to impaired antileukemic functionality of DC-stimulated T-cells. Ansprenger C; Vogt V; Schick J; Hirn-Lopez A; Vokac Y; Harabacz I; Braeu M; Kroell T; Karenberg A; Kolb HJ; Schmetzer H Cell Immunol; 2018 Jun; 328():33-48. PubMed ID: 29580554 [TBL] [Abstract][Full Text] [Related]
2. Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells. Vogt V; Schick J; Ansprenger C; Braeu M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H J Immunother; 2014; 37(6):331-47. PubMed ID: 24911794 [TBL] [Abstract][Full Text] [Related]
3. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions. Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655 [TBL] [Abstract][Full Text] [Related]
4. Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations. Schick J; Vogt V; Zerwes M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H J Immunother; 2013 May; 36(4):223-37. PubMed ID: 23603857 [TBL] [Abstract][Full Text] [Related]
5. Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts correlations of released chemokines with antileukemic T-cell reactions. Merle M; Fischbacher D; Liepert A; Grabrucker C; Kroell T; Kremser A; Dreyssig J; Freudenreich M; Schuster F; Borkhardt A; Kraemer D; Koehne CH; Kolb HJ; Schmid C; Schmetzer HM Immunobiology; 2021 May; 226(3):152088. PubMed ID: 33838552 [TBL] [Abstract][Full Text] [Related]
6. Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture. Unterfrauner M; Rejeski HA; Hartz A; Bohlscheid S; Baudrexler T; Feng X; Rackl E; Li L; Rank A; Filippini Velázquez G; Schmid C; Schmohl J; Bojko P; Schmetzer H Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139264 [TBL] [Abstract][Full Text] [Related]
7. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492 [TBL] [Abstract][Full Text] [Related]
8. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL. Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814 [TBL] [Abstract][Full Text] [Related]
9. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595 [TBL] [Abstract][Full Text] [Related]
10. Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients' Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays. Schutti O; Klauer L; Baudrexler T; Burkert F; Schmohl J; Hentrich M; Bojko P; Kraemer D; Rank A; Schmid C; Schmetzer H Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000091 [TBL] [Abstract][Full Text] [Related]
11. Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases. Baudrexler T; Boeselt T; Li L; Bohlscheid S; Boas U; Schmid C; Rank A; Schmohl J; Koczulla R; Schmetzer HM Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371569 [TBL] [Abstract][Full Text] [Related]
12. Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients' Response to Immunotherapy. Fischbacher D; Merle M; Liepert A; Grabrucker C; Kroell T; Kremser A; Dreyßig J; Freudenreich M; Schuster F; Borkhardt A; Kraemer D; Koehne CH; Kolb HJ; Schmid C; Schmetzer HM Cell Commun Adhes; 2015; 22(2-6):49-65. PubMed ID: 27602789 [TBL] [Abstract][Full Text] [Related]
13. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DC Ansprenger C; Amberger DC; Schmetzer HM Clin Immunol; 2020 Aug; 217():108467. PubMed ID: 32464186 [TBL] [Abstract][Full Text] [Related]
14. Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells. Schuster FR; Buhmann R; Reuther S; Hubner B; Grabrucker C; Liepert A; Reibke R; Lichtner P; Yang T; Kroell T; Kolb HJ; Borkhardt A; Schmetzer H Cancer Genomics Proteomics; 2008; 5(5):275-86. PubMed ID: 19129558 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775 [TBL] [Abstract][Full Text] [Related]
17. Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes. Rackl E; Li L; Klauer LK; Ugur S; Pepeldjiyska E; Seidel CL; Gunsilius C; Weinmann M; Doraneh-Gard F; Reiter N; Plett C; Amberger DC; Bojko P; Kraemer D; Schmohl J; Rank A; Schmid C; Schmetzer HM Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613907 [TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes. Ramadan G Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679 [TBL] [Abstract][Full Text] [Related]
19. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165 [TBL] [Abstract][Full Text] [Related]
20. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. Zhong RK; Loken M; Lane TA; Ball ED Cytotherapy; 2006; 8(1):3-12. PubMed ID: 16627340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]